Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 196


Global profiling and molecular characterization of alternative splicing events misregulated in lung cancer.

Misquitta-Ali CM, Cheng E, O'Hanlon D, Liu N, McGlade CJ, Tsao MS, Blencowe BJ.

Mol Cell Biol. 2011 Jan;31(1):138-50. doi: 10.1128/MCB.00709-10. Epub 2010 Nov 1.


Alternative splicing of NUMB, APP and VEGFA as the features of pancreatic ductal carcinoma.

Zheng KL, He TL, Ji WP, Jiang H, Shen Y, Li G, Zhu SB, Tong BL, Zhang YJ.

Int J Clin Exp Pathol. 2015 Jun 1;8(6):6181-91. eCollection 2015.


Alternative splicing of VEGFA, APP and NUMB genes in colorectal cancer.

Zhao YJ, Han HZ, Liang Y, Shi CZ, Zhu QC, Yang J.

World J Gastroenterol. 2015 Jun 7;21(21):6550-60. doi: 10.3748/wjg.v21.i21.6550.


Alterations of the Notch pathway in lung cancer.

Westhoff B, Colaluca IN, D'Ario G, Donzelli M, Tosoni D, Volorio S, Pelosi G, Spaggiari L, Mazzarol G, Viale G, Pece S, Di Fiore PP.

Proc Natl Acad Sci U S A. 2009 Dec 29;106(52):22293-8. doi: 10.1073/pnas.0907781106. Epub 2009 Dec 10.


Inhibition on Numb/Notch signal pathway enhances radiosensitivity of lung cancer cell line H358.

Song SG, Yu HY, Ma YW, Zhang F, Xu XY.

Tumour Biol. 2016 Oct;37(10):13705-13719. Epub 2016 Jul 30.


Identification of alternative splicing events regulated by the oncogenic factor SRSF1 in lung cancer.

de Miguel FJ, Sharma RD, Pajares MJ, Montuenga LM, Rubio A, Pio R.

Cancer Res. 2014 Feb 15;74(4):1105-15. doi: 10.1158/0008-5472.CAN-13-1481. Epub 2013 Dec 26.


Insight into the role of alternative splicing within the RBM10v1 exon 10 tandem donor site.

Tessier SJ, Loiselle JJ, McBain A, Pullen C, Koenderink BW, Roy JG, Sutherland LC.

BMC Res Notes. 2015 Feb 19;8:46. doi: 10.1186/s13104-015-0983-5.


Exon array analysis using re-defined probe sets results in reliable identification of alternatively spliced genes in non-small cell lung cancer.

Langer W, Sohler F, Leder G, Beckmann G, Seidel H, Gröne J, Hummel M, Sommer A.

BMC Genomics. 2010 Nov 30;11:676. doi: 10.1186/1471-2164-11-676.


HnRNP A1/A2 and SF2/ASF regulate alternative splicing of interferon regulatory factor-3 and affect immunomodulatory functions in human non-small cell lung cancer cells.

Guo R, Li Y, Ning J, Sun D, Lin L, Liu X.

PLoS One. 2013 Apr 29;8(4):e62729. doi: 10.1371/journal.pone.0062729. Print 2013.


Numb Gene Enhances Radiation Sensitivity of Nonsmall Cell Lung Cancer Stem Cells.

Shan GP, Zhang P, Li P, Du FL, Yang YW.

Cancer Biother Radiopharm. 2016 Jun;31(5):180-8. doi: 10.1089/cbr.2016.2053.


Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers.

Lin E, Li L, Guan Y, Soriano R, Rivers CS, Mohan S, Pandita A, Tang J, Modrusan Z.

Mol Cancer Res. 2009 Sep;7(9):1466-76. doi: 10.1158/1541-7786.MCR-08-0522. Epub 2009 Sep 8.


Reduced transcription of the RB2/p130 gene in human lung cancer.

Xue Jun H, Gemma A, Hosoya Y, Matsuda K, Nara M, Hosomi Y, Okano T, Kurimoto F, Seike M, Takenaka K, Yoshimura A, Toyota M, Kudoh S.

Mol Carcinog. 2003 Nov;38(3):124-9.


Chondrolectin is a novel diagnostic biomarker and a therapeutic target for lung cancer.

Masuda K, Takano A, Oshita H, Akiyama H, Tsuchiya E, Kohno N, Nakamura Y, Daigo Y.

Clin Cancer Res. 2011 Dec 15;17(24):7712-22. doi: 10.1158/1078-0432.CCR-11-0619. Epub 2011 Oct 20.


Expression and methylation pattern of TSLC1 cascade genes in lung carcinomas.

Heller G, Fong KM, Girard L, Seidl S, End-Pfützenreuter A, Lang G, Gazdar AF, Minna JD, Zielinski CC, Zöchbauer-Müller S.

Oncogene. 2006 Feb 9;25(6):959-68.


A proliferation-inducing ligand: a new biomarker for non-small cell lung cancer.

Sun B, Wang H, Wang X, Huang H, Ding W, Jing R, Shi G, Zhu L.

Exp Lung Res. 2009 Aug;35(6):486-500.


Identification and classification of differentially expressed genes in non-small cell lung cancer by expression profiling on a global human 59.620-element oligonucleotide array.

Hofmann HS, Bartling B, Simm A, Murray R, Aziz N, Hansen G, Silber RE, Burdach S.

Oncol Rep. 2006 Sep;16(3):587-95.


Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression.

Vonlanthen S, Heighway J, Tschan MP, Borner MM, Altermatt HJ, Kappeler A, Tobler A, Fey MF, Thatcher N, Yarbrough WG, Betticher DC.

Oncogene. 1998 Nov 26;17(21):2779-85.


Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer.

Rennstam K, McMichael N, Berglund P, Honeth G, Hegardt C, Rydén L, Luts L, Bendahl PO, Hedenfalk I.

Breast Cancer Res Treat. 2010 Jul;122(2):315-24. doi: 10.1007/s10549-009-0568-x. Epub 2009 Oct 1.


Reduced XPC messenger RNA level may predict a poor outcome of patients with nonsmall cell lung cancer.

Wu YH, Cheng YW, Chang JT, Wu TC, Chen CY, Lee H.

Cancer. 2007 Jul 1;110(1):215-23.


VEGFA upregulates FLJ10540 and modulates migration and invasion of lung cancer via PI3K/AKT pathway.

Chen CH, Lai JM, Chou TY, Chen CY, Su LJ, Lee YC, Cheng TS, Hong YR, Chou CK, Whang-Peng J, Wu YC, Huang CY.

PLoS One. 2009;4(4):e5052. doi: 10.1371/journal.pone.0005052. Epub 2009 Apr 1.

Supplemental Content

Support Center